Simple Summary The patient-derived xenograft (PDX) model is the in vivo standard for
cancer research as a preclinical platform. Besides its merits, we describe the general …

Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …

Establishing a valid in vitro model to represent tumor heterogeneity and biology is critical but
challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are …

While chemotherapy alone or in combination with radiotherapy and surgery are important
modalities in the treatment of colorectal cancer, their widespread use is not paired with an …

Human organoid models potentially offer a physiologically relevant platform to replace
traditional monolayer cultures and animal models. In particular, the rapid development of …

Background The inability to predict treatment response of colorectal cancer patients results
in unnecessary toxicity, decreased efficacy and survival. Response testing on patient …

Biomedical research has long relied on animal models to unravel the intricacies of human
physiology and pathology. However, concerns surrounding ethics, expenses, and inherent …

Simple Summary Colorectal cancer is the third most commonly diagnosed cancer. Patients
may receive chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or surgery …

An accumulation of previous work has established organoids as good preclinical models of
human tumors, facilitating translation from basic research to clinical practice. They are …

Background Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from
molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an …